MMP-1 (Recombinant)
- Expression system
- HEK293
- Cat. #
- REC-MMP1
In stock
- SKU
- REC-MMP1
Target Overview
MMP-1 (Matrix metalloproteinase-1; interstitial collagenase; EC 3.4.24.7; UniProt P03956) is a secreted zinc-dependent endopeptidase of the metzincin superfamily. The full-length human protein spans 469 amino acids and comprises a signal peptide, propeptide, catalytic domain bearing the conserved HEXXHXXGXXH zinc-binding motif, and a C-terminal hemopexin-like domain that confers substrate specificity for fibrillar collagens. This recombinant is produced in HEK293 cells, providing the mammalian post-translational processing — including N-linked glycosylation — characteristic of the native secreted enzyme. HEK293 expression is preferred over prokaryotic systems when correctly folded, glycosylated enzyme is required for accurate kinetic measurements or protein–protein interaction studies. MMP-1 is the prototypic interstitial collagenase: it cleaves the triple helix of fibrillar collagens I, II, and III at a single conserved Gly–Leu/Ile bond in the helical domain, initiating their irreversible degradation. It also cleaves collagens VII and X. Recombinant MMP-1 is routinely used for substrate cleavage assays with fluorogenic (e.g., Mca-PLGL-Dpa-AR-NH₂) or gelatin-based substrates, and for determining the IC₅₀ of candidate small-molecule or peptide inhibitors against a defined enzyme preparation. As an antibody validation standard, this recombinant provides a well-characterised positive-control antigen for Western blot titration, dot-blot assay optimisation, and ELISA standard-curve construction. Researchers using this recombinant for antibody validation can pair it directly with the matched Triple Point Biologics anti-MMP-1 antibody (SKU: RP-MMP1), which has been validated for Western blot. Biophysical applications include surface plasmon resonance (SPR) and biolayer interferometry (BLI) binding studies with TIMP-1, TIMP-2, or candidate inhibitory peptides.
Background
Applications
- Fluorogenic substrate cleavage activity assay (e.g., Mca-PLGL-Dpa-AR-NH₂) to confirm lot-to-lot enzymatic activity
- Inhibitor IC50 determination for small molecules, peptides, or natural product extracts against defined recombinant MMP-1 concentrations
- TIMP-1 and TIMP-2 binding characterisation by surface plasmon resonance (SPR) or biolayer interferometry (BLI)
- Antibody validation positive control for Western blot and dot-blot assays — pair with matched Triple Point Biologics anti-MMP-1 antibody (SKU: RP-MMP1)
- ELISA standard curve construction and spike-recovery validation in collagen remodelling panels
- Collagen type I, II, or III triple-helix cleavage assays monitored by SDS-PAGE or mass spectrometry to confirm substrate specificity
- Zymography reference standard for comparison with endogenous MMP-1 activity in conditioned media samples
- Substrate identification or cleavage-site mapping studies by mass spectrometry using defined recombinant enzyme preparations
References
- Xu R et al. Combining Network Pharmacology, Machine Learning, Molecular Docking, and Experimental Validation to Explore the Mechanism of Danggui-Shaoyao-San in treating Rheumatoid arthritis. Curr Pharm Des. 2026. doi:10.2174/0113816128431656260305144620. PMID: 42337901.
- Hong S et al. Vaginal dysbiosis and inflammatory signatures in preterm labor: an integrated model for predicting preterm birth. Front Immunol. 2026. doi:10.3389/fimmu.2026.1809046. PMID: 42327783.
- Wang N et al. Identification of Biomarker in Kidney Stone Disease by Integrating Transcriptomics and Olink Proteomics: A Case-Control Study. J Inflamm Res. 2026. doi:10.2147/JIR.S605025. PMID: 42306184.
- Tian L et al. Targeted discovery of anti-skin aging peptides from Camelus bactrianus placenta: Multi-activity screening, network pharmacology, and in vitro validation focusing on MMP-1 inhibition. J Ethnopharmacol. 2026. doi:10.1016/j.jep.2026.122064. PMID: 42302941.
- Borikun T. Stress-Induced Changes in the Methylation Status of Mmp1 and Mmp8 Genes in Tumor Tissue of Rats with Guerin Carcinoma. Exp Oncol. 2026. doi:10.15407/exp-oncology.2026.01.046. PMID: 42290557.
Additional Specifications
| Storage Buffer | 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol |
|---|---|
| Endotoxin Level | <0.1 EU/µg by LAL |
| Purity (%) | >90% by SDS-PAGE |
| Expression System | HEK293 |
| Subcellular Localization | Secreted; Extracellular matrix |
Frequently Asked Questions
What molecular weight band should I expect for recombinant MMP-1 on SDS-PAGE or Western blot?
Under reducing SDS-PAGE conditions, this HEK293-expressed recombinant MMP-1 typically runs at approximately 52–57 kDa — slightly above the theoretical 54 kDa of the processed proenzyme — owing to N-linked glycosylation added during mammalian expression. The latent proform (full-length minus signal peptide) is ~54 kDa; autocatalytic or APMA-activated enzyme loses the ~10 kDa propeptide to yield a ~44–46 kDa active species. If you are running the protein before activation, expect the higher band. Run alongside a broad-range MW ladder and include an APMA-treated lane to distinguish pro- versus active forms.
Which isoform or processing form is this recombinant MMP-1 — proenzyme or active enzyme?
The product is supplied as the active enzyme form: the propeptide has been removed during production and quality control processing in HEK293 cells. The catalytic domain and C-terminal hemopexin-like domain (residues ~100–469 of the full-length sequence, post signal peptide cleavage) are both present, preserving the substrate-specificity determinants required for fibrillar collagen recognition. This is particularly relevant if you need the hemopexin domain for collagen-binding or protein–protein interaction assays — truncated catalytic-domain-only constructs produced in E. coli would lack this region.
What substrates and assay conditions should I use to confirm MMP-1 activity in a fluorescent peptide assay?
A standard choice is the fluorogenic peptide substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (also sold as MMP Substrate III), used at 10–20 µM in assay buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM CaCl2, 0.05% Brij-35. Recombinant MMP-1 at 1–5 nM final concentration is typically sufficient to generate a linear signal over 30–60 min at 37 °C (excitation ~320 nm, emission ~405 nm). Avoid EDTA or EGTA in the assay buffer — they chelate the catalytic zinc and will abolish activity. Include a no-enzyme blank and a 10 mM EDTA-inhibited control.
What starting concentration of recombinant MMP-1 should I use for collagen degradation or inhibitor IC50 assays?
For fluorogenic peptide-based IC50 determinations, 1–5 nM MMP-1 is a practical starting point; working below the Km of your substrate (~5–20 µM for most Mca-based peptides) keeps the assay in a substrate-excess regime where competitive inhibitor IC50 approximates Ki. For native fibrillar collagen degradation assays (e.g., type I collagen gel contraction or SDS-PAGE collagen cleavage), 10–50 nM enzyme is typically required for visible cleavage within 4–24 h at 37 °C. Titrate enzyme concentration in a preliminary experiment before running inhibitor panels to confirm linearity of signal with respect to enzyme amount.
Does the storage buffer for recombinant MMP-1 interfere with downstream activity assays or cell-based experiments?
The supplied buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2 — is compatible with most biochemical activity assays at typical working dilutions of 1:10 to 1:100. Glycerol at final concentrations below 1% is generally well tolerated. For cell-based experiments, dilute at least 1:20 into serum-free medium to reduce glycerol to ≤0.5% and verify that exogenous CaCl2 at the resulting concentration (~0.25 mM) does not perturb your cell model. Avoid further dilution into EDTA- or EGTA-containing buffers, as these will chelate the calcium required for metalloproteinase stability and activity.
How should I store recombinant MMP-1 and how many freeze-thaw cycles are acceptable?
Store at −20 °C in the single-use aliquots as supplied. Each aliquot is sized to minimize the need for refreezing. Repeated freeze-thaw cycles cause progressive loss of metalloproteinase activity — we recommend no more than two cycles before discarding unused material. For working stocks needed across multiple days, prepare dilutions in assay buffer containing 0.1% BSA and store at 4 °C for up to 48 h. Do not store diluted enzyme at −20 °C without a carrier protein, as adsorption to tube walls at low concentrations will reduce effective activity.
Can I use recombinant MMP-1 as a positive control for Western blot with the matched TPB anti-MMP-1 antibody (RP-MMP1)?
Yes — this is a primary validation use case. Load 20–50 ng of recombinant MMP-1 per lane alongside your cell lysate or conditioned medium samples. The matched rabbit polyclonal antibody RP-MMP1 (see /anti-mmp-1-rabbit-polyclonal-antibody) is raised against MMP-1 and validated for Western blot, so it will detect the recombinant at the expected ~52–57 kDa (proform) or ~44–46 kDa (active form). This pairing is especially useful for confirming antibody performance on new membrane types or blocking conditions, and for setting exposure parameters before running precious biological samples.
How much recombinant MMP-1 should I load as a Western blot positive control, and what band should RP-MMP1 antibody detect?
Load 20–50 ng of recombinant MMP-1 per lane for a clean, non-saturated signal with RP-MMP1 at recommended dilutions (typically 1:500–1:2000 for Western blot — confirm on the RP-MMP1 datasheet). At 20 ng you should see a distinct band at ~52–57 kDa if the proform predominates, or ~44–46 kDa for the fully processed active enzyme. If signal is faint at 20 ng, increase to 50 ng before adjusting antibody concentration. Because both the recombinant and RP-MMP1 originate from the same TPB platform, lot-to-lot compatibility is confirmed — no need to re-validate the pairing when either reagent is re-ordered.
Validation imagery coming soon
Western blot validation figures for REC-MMP1 will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.